Welcome!

JASTLabs has developed a new pharmaceutical for one of the most widespread and persistent unmet needs in women's health globally. This is menopause-related vaginal atrophy and diminished libido. These symptoms affect over one billion women worldwide and significantly impair quality of life, comfort, and intimate relationships. In this sense, our solution not only helps women, but also their life partners indirectly. There is a wide quality-of-life benefit.

Existing estrogen-based treatments carry widely known risks and contraindications, leaving many women without a safe, effective long-term option.

JASTLabs has developed "JL-112", a patent-pending, non-estrogen prescription vaginal cream that combines oxytocin and sildenafil citrate in a stable, topical formulation. This approach is designed to relieve vaginal atrophy symptoms and improve libido without the cancer, cardiovascular, or thrombotic risks associated with estrogen therapies. The formulation has achieved room-temperature stability and is intended for simple, self-administration, once-daily. Before we commercialize, we need to pass through the next stage of U.S. FDA approval for the USA, and other national bodies internationally. We are following a disciplined business model that targets an accelerated regulatory pathway, 505(b)(2). This is a mechanism to pursue commercialization sooner than usual for conventional new pharmaceutical introductions, while maintaining rigorous quality and safety standards.

Our 32 published claims within the international patent treaty (PCT) cover the core composition, specific dosages, manufacturing process, stability characteristics, and multiple therapeutic uses. We are pursuing protection in 58 countries with an aggregate population of over 1 billion women aged 35+. These are the key markets for commercialization over the next 20 years. Full roll-out of this patent strategy would result in JASTLabs' lead product being one of the best protected women's health topical solutions ever.

JASTLabs is led by an exceptionally experienced management team. This includes proven pharmaceutical, regulatory, and commercialization track records. Our CEO has been involved with some of the world's best known and successful pharmaceuticals, over many years, with extensive executive responsibility.

In short, JL-112 represents a distinct new therapeutic category. It has key characteristics for substantial commercial success in a large, recurring-use market, worldwide.

Accredited investors are being given an early on-ramp with Preferred Shares, effective immediately, under SEC Regulation D (Rule 506 (c)). This will be followed by an intended launch of Common Shares later in 2026 via a general public offering under SEC Regulation A+. The combined offering is $75 Million. Details of the offering are described in a formal Private Offering Memorandum available on an online offering page hosted by Manhattan Street Capital (link below). Your participation in this investment can be activated through that Offering Page. All necessary resources, details and investment payment steps are provided there for your convenience. A member of JASTLabs Coordinating Team is available at any time to answer questions and provide assistance. The email address for assistance is: InvestorAssistance@JASTLabs.com

It would be our pleasure to welcome you into the community of owners of JASTLabs Corporation. Delivering a breakthrough pharmaceutical for women globally, and joining the ranks of pharma industry success stories is our business goal. The pharmaceutical sector is consistently among the world's most successful because of the immense benefit it delivers, and the practice of building on intellectual property protection. JASTLabs Corporation is launching in this sector, in this model. Thank you for your interest.